Patent: 9,187,565
✉ Email this page to a colleague
Summary for Patent: 9,187,565
| Title: | Antibodies against CD38 for treatment of multiple myeloma |
| Abstract: | Isolated human monoclonal antibodies which bind to human CD38, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the human antibodies, and therapeutic and diagnostic methods for using the human antibodies. |
| Inventor(s): | De Weers Michel, Graus Yvo, Oprins Judith, Parren Paul, Van De Winkel Jan, Van Vugt Martine |
| Assignee: | GENMAB A/S |
| Application Number: | US12886930 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,187,565
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | DARZALEX | daratumumab | Injection | 761036 | November 16, 2015 | ⤷ Start Trial | 2030-09-21 |
| Janssen Biotech, Inc. | DARZALEX FASPRO | daratumumab and hyaluronidase-fihj | Injection | 761145 | May 01, 2020 | ⤷ Start Trial | 2030-09-21 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 9,187,565
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Africa | 200709003 | ⤷ Start Trial |
| World Intellectual Property Organization (WIPO) | 2006099875 | ⤷ Start Trial |
| United States of America | 7829673 | ⤷ Start Trial |
| United States of America | 2024228662 | ⤷ Start Trial |
| United States of America | 2024132620 | ⤷ Start Trial |
| United States of America | 2020283542 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
